Related Experiment Video
Updated: May 27, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Anacetrapib: a new weapon against dyslipidemia.
Georgios Aperis1, Christos Paliouras, Eirini Tsampikaki
1Nephrology Department, General Hospital of Rhodes, Agioi Apostoloi, Greece. gaperis@yahoo.com
Current Clinical Pharmacology
|November 16, 2011
Summary
Anacetrapib, a cholesteryl-ester-transfer-protein (CETP) inhibitor, effectively lowers LDL cholesterol and raises HDL cholesterol. Clinical trials indicate it is safe, but long-term studies are needed to confirm cardiovascular benefits.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Metabolic Disorders
Background:
- Anacetrapib is an experimental cholesteryl-ester-transfer-protein (CETP) inhibitor.
- It targets primary hypercholesterolemia and dyslipidemia linked to metabolic syndrome.
Purpose of the Study:
- To evaluate the efficacy and safety of anacetrapib.
- To assess its impact on lipid profiles, specifically LDL-C and HDL-C levels.
Main Methods:
- Review of Phase I, II, and III clinical trial data.
- Analysis of anacetrapib's effects when used alone and with statins.
Main Results:
- Anacetrapib significantly decreases low-density lipoprotein cholesterol (LDL-C).
- It substantially increases high-density lipoprotein cholesterol (HDL-C).
- Clinical trials demonstrated anacetrapib's safety profile.
Conclusions:
- Anacetrapib shows promise as a treatment for hypercholesterolemia and dyslipidemia.
- Further long-term clinical trials are necessary to determine its effect on cardiovascular mortality in high-risk individuals.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:24Lipid Absorption
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:06Lipid Digestion
Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...